Cargando…
‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury
Infants born at very low gestational age contribute disproportionately to neonatal morbidity and mortality. Advancements in antenatal steroid therapies and surfactant replacement have favored the survival of infants with ever-more immature lungs. Despite such advances in medical care, cardiopulmonar...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876073/ https://www.ncbi.nlm.nih.gov/pubmed/28985201 http://dx.doi.org/10.1038/pr.2017.256 |
_version_ | 1783310455990648832 |
---|---|
author | Willis, Gareth R Mitsialis, S. Alex Kourembanas, Stella |
author_facet | Willis, Gareth R Mitsialis, S. Alex Kourembanas, Stella |
author_sort | Willis, Gareth R |
collection | PubMed |
description | Infants born at very low gestational age contribute disproportionately to neonatal morbidity and mortality. Advancements in antenatal steroid therapies and surfactant replacement have favored the survival of infants with ever-more immature lungs. Despite such advances in medical care, cardiopulmonary and neurological impairment prevail in constituting the major adverse outcomes for neonatal intensive care unit (NICU) survivors. With no single effective therapy for either the prevention or treatment of such neonatal disorders, the need for new tools to treat and reduce risk of further complications associated with extreme preterm birth is urgent. Mesenchymal stem/stromal cell (MSC)-based approaches have shown promise in numerous experimental models of lung injury relevant to neonatology. Recent studies have highlighted that the therapeutic potential of MSCs is harnessed in their secretome, and that the therapeutic vector therein is represented by the exosomes released by MSCs. In this review, we summarize the development and significance of stem cell-based therapies for neonatal diseases, focusing on preclinical models of neonatal lung injury. We emphasize the development of MSC exosome-based therapeutics and comment on the challenges in bringing these promising interventions to clinic. |
format | Online Article Text |
id | pubmed-5876073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-58760732018-05-22 ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury Willis, Gareth R Mitsialis, S. Alex Kourembanas, Stella Pediatr Res Article Infants born at very low gestational age contribute disproportionately to neonatal morbidity and mortality. Advancements in antenatal steroid therapies and surfactant replacement have favored the survival of infants with ever-more immature lungs. Despite such advances in medical care, cardiopulmonary and neurological impairment prevail in constituting the major adverse outcomes for neonatal intensive care unit (NICU) survivors. With no single effective therapy for either the prevention or treatment of such neonatal disorders, the need for new tools to treat and reduce risk of further complications associated with extreme preterm birth is urgent. Mesenchymal stem/stromal cell (MSC)-based approaches have shown promise in numerous experimental models of lung injury relevant to neonatology. Recent studies have highlighted that the therapeutic potential of MSCs is harnessed in their secretome, and that the therapeutic vector therein is represented by the exosomes released by MSCs. In this review, we summarize the development and significance of stem cell-based therapies for neonatal diseases, focusing on preclinical models of neonatal lung injury. We emphasize the development of MSC exosome-based therapeutics and comment on the challenges in bringing these promising interventions to clinic. 2017-11-22 2018-01 /pmc/articles/PMC5876073/ /pubmed/28985201 http://dx.doi.org/10.1038/pr.2017.256 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Willis, Gareth R Mitsialis, S. Alex Kourembanas, Stella ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury |
title | ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury |
title_full | ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury |
title_fullStr | ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury |
title_full_unstemmed | ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury |
title_short | ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury |
title_sort | ‘good things come in small packages’: application of exosome-based therapeutics in neonatal lung injury |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876073/ https://www.ncbi.nlm.nih.gov/pubmed/28985201 http://dx.doi.org/10.1038/pr.2017.256 |
work_keys_str_mv | AT willisgarethr goodthingscomeinsmallpackagesapplicationofexosomebasedtherapeuticsinneonatallunginjury AT mitsialissalex goodthingscomeinsmallpackagesapplicationofexosomebasedtherapeuticsinneonatallunginjury AT kourembanasstella goodthingscomeinsmallpackagesapplicationofexosomebasedtherapeuticsinneonatallunginjury |